foreign exchange, the Company reported net loss of Baht 102.0 million. Loss per share reported at Baht 4.78. Statement of Comprehensive Income Total Revenues (Million Baht) Quarterly Change 1/2020 1/2019
www.interpharma.co.th IP_OCS/010/2562 November 10, 2019 Subject Management’s discussion and analysis for the third quarter of 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited (“the
the Company in Q1/2023 Q1/22 Q1/23 Change +/(-) (THB million) %YoY Operating Revenue 198 264 33% Cost of Sales (78) (96) (23%) Gross Profit 120 168 40% Other income 3 4 33% Selling and Distribution
Income from Utilities Business2 3.0 21.9 (86.3%) 4.4 32.3 (86.5%) Costs of Sales and Services (279.4) (272.2) 2.7% (552.4) (530.6) 4.1% Gross Profit 144.0 133.3 8.1% 293.0 262.9 11.5% Gross Profit from
17.91% in 2018 compared to 15.50% in 2017. Details of the management discussion and analysis follow: Income statements 2018 Operational Performance The Company reported Revenues from hospital operations
in 2018, with Net profit margin at 17.60% in 2019 compared to 17.91% in 2018. Details of the management discussion and analysis as follow: Income Statements 2019 Operational Performance The Company
received more automated system work, thus unable to control the installation time as projected in some projects. - Other income decreased 88.05% from the same period of last year due to in 2017, the Company
VGI PUBLIC COMPANY LIMITED BUSINESS HIGHLIGHTS 1Q 2020/21 Our overall performance was significantly affected by COVID-19 pandemic. Total revenue was THB 445mn, a decrease of 50.6% YoY. o o Gross
million, decreasing Baht 2,221 million or 25.23 percent, over-quarter. The decrease could be attributed to non-interest income which fell Baht 8,785 million, or 54.37 percent, due mainly to the volatility
Ref. No. 1805/025EN May 14, 2018 Subject Management Discussion and Analysis for Q1/2018 (Ending March 31, 2018) To Director and Manager of the Stock Exchange of Thailand Ubis (Asia) Public Company